1990s trial gave early danger signs for asthma drugs

November 25, 2012 by John Fauber

The troubled history of asthma drugs known as long-acting beta-agonists goes back to the 1990s when a large clinical trial in Great Britain of the GlaxoSmithKline drug Serevent produced disturbing results.

In that 16-week trial of 25,000 , 12 people getting the drug died of and respiratory causes, compared with only two in the who took a standard medication, according to a 1993 paper.

In addition, there were 193 hospitalizations or life-threatening events related to asthma and respiratory causes in the users of the new drug, compared with 102 in the other group.

The serious concerns raised in the first trial of Serevent, also known as salmeterol, led to a second large study of the drug several years later in the United States.

That trial was halted by , in part because of excess deaths among African-Americans.

Researchers had hoped to study 60,000 people in the trial, but only 26,000 people had been enrolled when it was stopped in 2003.

A 2006 paper that detailed the results of the U.S. trial noted there were 37 asthma and respiratory related deaths in those receiving salmeterol, compared with 14 among those on usual who also got a placebo.

Among African-Americans getting salmeterol, 15 died of asthma and respiratory causes during the 28-week study period, compared with only three who got a placebo.

It is not known why African-Americans may be more vulnerable to the effects of salmeterol. One theory involves genetic variations in cells in the lungs.

Long-acting beta-agonists are inhaled drugs that are sold as single agents. They also can be combined in an with a steroid.

The leading beta-agonist/steroid combination product is Advair, sales of which have topped $4 billion a year since 2007, according to the market research firm IMS Health.

Another long-acting beta-agonist, Foradil (formoterol) also is available as a single-agent and as the combined product Symbicort, made by AstraZeneca.

In an email, GlaxoSmithKline spokeswoman Karen Collins said studies consistently have shown that Advair provides better overall asthma control than just an inhaled corticosteroid, including improvements in lung function, symptom control and less use of short-acting rescue inhalers.

She said both Advair and Serevent have improved asthma care.

"These medicines are used by millions of people worldwide and in the vast majority of people treated, they are well tolerated," she said.

Explore further: Stopping controversial asthma drugs could have downside: study

Related Stories

Stopping controversial asthma drugs could have downside: study

August 27, 2012
(HealthDay)—It's OK for some patients with asthma to stick with a combination of medications instead of abandoning one because of concerns about complications, a new analysis of existing research suggests.

Combined asthma medication therapy shown to reduce attacks

February 6, 2012
A Henry Ford Hospital study has found that using two types of common asthma medications in combination reduces severe asthma attacks.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.